Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Parents are integral in stopping rise as teen e-cigarette usage triples

  • Anti-stroke drug effective treatment for middle-ear infections, researchers say

  • Implantable micro-device to monitor oxygen in glioma to improve treatment outcomes

  • Study on neurogenesis in the olfactory bulb

  • Raising a glass to the holidays: Research finds extra alcohol sold, consumed on holidays

  • Human stem cell model reveals molecular cues critical to neurovascular unit formation

  • Scientists create mice with a major genetic cause of ALS, frontotemporal dementia

  • Blood test for Alzheimer's one step closer

  • Switching off brain circuit renders mice 'out of touch' with environment

  • Facebook status updates reveal low self-esteem and narcissism

  •